All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-522164
DOI to cite this document:: 10.5283/epub.52216

Heudobler, Daniel ; Fante, Matthias A. ; Felsensteiner, Mona ; Mayer, Stephanie ; Gerken, Michael ; Klinkhammer-Schalke, Monika ; Herr, Wolfgang ; Vogelhuber, Martin ; Reichle, Albrecht

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 28 Apr 2022 10:45

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

PurposeTreatment options in patients (pts.) with advanced relapsed and refractory aggressive B-cell lymphoma are limited. Palliative all-oral chemotherapy regimens reduce in-patient visits and contribute to quality of life. The all-oral low-dose chemotherapy regimen TEPIP comprises the conventional chemotherapy agents trofosfamide, etoposide, procarbazine, idarubicin and prednisolone. ...